Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent
Authors:
Open Access
- 1 June 1993
- journal article
- Published by American Society of Hematology in Blood
- Vol. 81 (11) , 2878-2884
Abstract
The clinical response and survival of 113 patients with at least 3-year follow-up after treatment with fludarabine as a single agent for chronic lymphocytic leukemia has been evaluated. Seventy-eight patients were previously treated and 35 were untreated. The response to therapy and survival were strongly correlated with the degree of previous therapy, the stage of disease, and whether or not the patients were refractory to alkylating agents. Other characteristics associated with survival were the age of the patient and the serum albumin level at the start of therapy. The median time to progression of responders who had not received prior therapy was 33 months and was 21 months for previously treated patients. Survival after progression of disease was also strongly correlated with the degree of prior therapy. No successful salvage regimen after initial fludarabine therapy was shown for patients refractory to alkylating agents, although fludarabine achieved further remissions in patients who had received fludarabine as their initial treatment or were not refractory to alkylating agents. The morbidity of patients in unmaintained remission on discontinuation of fludarabine was low, with less than one episode of infection per patient-year at risk. The morbidity during this time was correlated with clinical response and whether the patients had received prior therapy. Although fludarabine is a very effective cytoreductive regimen, most patients, including those who achieved true complete remissions, will have recurrent disease. Longer follow-up and comparative trials are required before the effect of fludarabine on survival is shown.Keywords
This publication has 8 references indexed in Scilit:
- Response to 2-Chlorodeoxyadenosine in Patients with B-Cell Chronic Lymphocytic Leukemia Resistant to FludarabineNew England Journal of Medicine, 1992
- Kinetics of Recovery of CD4+ T Cells in Peripheral Blood of Deoxycoformycin-Treated PatientsJNCI: Journal of the National Cancer Institute, 1991
- A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia.Journal of Clinical Oncology, 1991
- Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial.Journal of Clinical Oncology, 1991
- Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.Journal of Clinical Oncology, 1991
- 2-Chlorodeoxyadenosine Treatment of Refractory Chronic Lymphocytic LeukemiaLeukemia & Lymphoma, 1991
- Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working groupAmerican Journal of Hematology, 1988
- Malignant lymphoma supervening in chronic lymphocytic leukemia and related disorders. Richter's syndrome: A study of 25 casesCancer, 1981